Evidence map›Paper›PMID 41645068›Full record

ArticleBMC medical research methodology2026

Correction: Randomization in the age of platform trials: unexplored challenges and some potential solutions.

Olga Kuznetsova, Jennifer Ross, Daniel Bodden, Freda Cooner, Jonathan Chipman, Peter Jacko, Johannes Krisam, Yuqun Abigail Luo, Tobias Mielke, David S Robertson and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medical research methodology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Olga KuznetsovaMerck & Co., Inc, Rahway, NJ, USA.
Jennifer RossAlmac Group, Souderton, PA, USA.
Daniel BoddenRWTH Aachen University, Aachen, Germany.
Freda CoonerFood and Drug Administration, Silver Spring, MD, USA.
Jonathan ChipmanUniversity of Utah School of Medicine, Salt Lake City, UT, USA.
Peter JackoBerry Consultants, Lancaster University, Abingdon, Lancaster, Oxfordshire, UK.
Johannes KrisamBoehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Yuqun Abigail LuoFood and Drug Administration, Silver Spring, MD, USA.
Tobias MielkeJanssen-Cilag GmbH, Neuss, Germany.
David S RobertsonMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
Yevgen RyeznikDepartment of Mathematics, Uppsala University, Uppsala, Sweden. yevgen.ryeznik@math.uu.se.
Sofia S VillarMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
Wenle ZhaoMedical University of South Carolina, Charleston, SC, USA.
Oleksandr SverdlovNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA. alex.sverdlov@novartis.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41645068
PMCPMC12874853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.